Drawing for REJUVANAD+

USPTO serial 79425415

REJUVANAD+

Reviewed by CopyMark Law Group

Reg. 8397085Status 700Registered
Filing date
Status date
Registration date
Aug 18, 2026
Examiner
GUZICK, LEAH A
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with REJUVANAD+?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kisuk Lee

Kisuk Lee Attorney of Record, Missouri Bar Member7700 Bonhomme Avenue, Suite 400Saint Louis, MO 63105United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of age-related cellular decline; pharmaceutical preparations for anti-aging purposes; pharmaceutical preparations for cognitive enhancement and mental clarity; pharmaceutical preparations for boosting energy levels and treating fatigue; pharmaceutical preparations for supporting DNA repair; pharmaceutical preparations for cellular rejuvenation and metabolic support; pharmaceutical preparations for physical recovery; Pharmaceutical compositions, namely, nicotinamide adenine dinucleotide (NAD+) preparations for medical use, namely, for the treatment of cellular aging; pharmaceutical compositions, namely, coenzyme preparations for medical use, namely, for the treatment of cellular aging; pharmaceutical compositions, namely, anti-aging pharmaceutical preparations for the treatment of cellular aging; Pharmaceutical drugs for the treatment of age-related cellular decline; pharmaceutical drugs for the treatment of fatigue; pharmaceutical drugs for the treatment of cognitive impairment; pharmaceutical drugs for the treatment of metabolic disorders; Cough pastilles for medical use; Medicinal infusions for treating fatigue and age-related conditions; Medicine preparations for human use for anti-aging purposes; medicine preparations for human use for cellular health support; medicine preparations for human use for the treatment of age-related conditions and fatigue; Non-prescription medicine preparations for general health and wellness support; non-prescription medicine preparations for anti-aging support; non-prescription medicine preparations for energy and vitality support; Pre-filled syringes containing nicotinamide adenine dinucleotide (NAD+) for medical purposes; prefilled syringes containing pharmaceutical preparations for anti-aging and cellular rejuvenation, for medical purposes; Pharmaceutical preparations for antiaging skin care; Anti-aging pharmaceutical compositions for skin care; Pharmaceutical preparations for skin care; Medicated skin care preparations for medical purposes; Medicated skin care preparations; Injectable dermal fillers for medical purposes; Medicated creams for skin care and protection of the skin; all the foregoing containing nicotinamide adenine dinucleotideACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 4, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Nov 3, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Aug 18, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 18, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 30, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 30, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 25, 2026GPNXNOTIFICATION PROCESSED BY IB—
Jun 24, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 10, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jun 10, 2026OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jun 1, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 22, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 22, 2026XAECEXAMINER'S AMENDMENT ENTERED—
May 22, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
May 22, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Apr 27, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 27, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 27, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 27, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 27, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 27, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 27, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Nov 15, 2025RFNTREFUSAL PROCESSED BY IB—
Oct 27, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 27, 2025RFRRREFUSAL PROCESSED BY MPU—
Sep 9, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 8, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2025DOCKASSIGNED TO EXAMINER—
Jun 6, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 6, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 5, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance